The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate)

Friday, May 25, 2012

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate)08:30 EDT Friday, May 25, 2012Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual MeetingNEW BRUNSWICK, N.J., May 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology's (ASCO) Annual Meeting  in Chicago, Ill.  Results from pre-specified interim analyses of COU-AA-302, a randomized, phase 3 study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer, will be shown for the first time at ASCO.The pre-recorded webcast with management from the Company's Janssen pharmaceutical subsidiaries, will provide an update on the results of the COU-AA-302 study and an update on the initial launch of ZYTIGA® (abiraterone acetate). The webcast/podcast and replay can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."SOURCE Johnson & JohnsonFor further information: Investor Contacts: Stan Panasewicz, +1-732-524-2524 or Louise Mehrotra, +1-732-524-6491; Press Contacts: Al Wasilewski, +1-732-524-1130 or Bill Price, +1-732-524-6623